Diarrhea News and Research

Latest Diarrhea News and Research

Infection control program and active surveillance can reduce incidence of impatient C. diff infections

A comprehensive infection control program combined with an active surveillance process significantly reduced the incidence of Clostridium difficile (C. diff) infections in a long-term acute care hospital, according to a study published in the Journal for Healthcare Quality, the peer reviewed publication of the National Association for Healthcare Quality (NAHQ).

10 Jul 2013

Soligenix announces personalized medicine collaboration with SciClone

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced a personalized medicine collaboration with SciClone Pharmaceuticals in the Company's oral mucositis clinical program with SGX942.

8 Jul 2013

Study identifies genomic regions associated with cholera susceptibility

An international research team has used a novel approach to identify genetic factors that appear to influence susceptibility to cholera. The findings by investigators from Massachusetts General Hospital (MGH), the Broad Institute and the International Center for Diarrh-al Disease Research, Bangladesh (ICDDR,B) indicate the importance of pathways involved in regulating water loss in intestinal cells and of the innate immune system in the body's response to the bacteria that causes cholera, which affects from 3 to 5 million people each year and causes more than 100,000 deaths.

4 Jul 2013

Scientists uncover easy strategies to prevent harmful side-effects of antibiotics responses

A team of scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University has discovered why long-term treatment with many common antibiotics can cause harmful side effects-and they have uncovered two easy strategies that could help prevent these dangerous responses.

4 Jul 2013

Researchers report that aerobic exercise can lessen or worsen ulcerative colitis symptoms

Aerobic exercise can lessen - or worsen - the symptoms of inflammatory bowel diseases such as ulcerative colitis, depending on the circumstances under which the exercise is undertaken, researchers report.

3 Jul 2013

ARIAD Pharmaceuticals' Iclusig gets EC marketing authorization for CML and Ph+ ALL treatment

ARIAD Pharmaceuticals, Inc. today announced that the European Commission has granted a marketing authorization for Iclusig (ponatinib) as an orphan medicinal product for two indications.

2 Jul 2013

Genentech's Perjeta regimen gets FDA Priority Review for HER2-positive early stage breast cancer

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application for the use of a Perjeta (pertuzumab) regimen before surgery (neoadjuvant treatment) in people with HER2-positive early stage breast cancer.

2 Jul 2013

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration and an application for marketing authorization to the European Medicines Agency for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

1 Jul 2013

First clinical study for development of SGX203 to treat pediatric Crohn's disease

Soligenix, Inc. (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has enrolled and treated all patients in the Phase 1 Study BDP-PCD-01; the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease.

1 Jul 2013

EMA's CHMP issues positive opinion for approval of Genzyme's LEMTRADA in Europe

Genzyme, a Sanofi company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for approval of LEMTRADA (alemtuzumab) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features.

28 Jun 2013

FDA approves Novartis' Exelon Patch for treatment of severe Alzheimer's disease

The US Food and Drug Administration has expanded the approved indication for Exelon Patch (rivastigmine transdermal system) to include the treatment of people with severe Alzheimer's disease with Exelon Patch 13.3mg/24h.

28 Jun 2013

Physician offers helpful tips to a healthy summer

Summer is officially here, and for many, so is the threat of sunburn, bug bites and allergies. Deepti Shivakumar, MD, family practice at Gottlieb Memorial Hospital, offers some helpful tips to a healthy summer.

27 Jun 2013

Eisai submits BELVIQ NDS with Health Canada

Arena Pharmaceuticals, Inc. announced today that Eisai Limited (based in Mississauga, Ontario), a subsidiary of Eisai Inc., has submitted a New Drug Submission for BELVIQ (lorcaserin HCl) with Health Canada.

26 Jun 2013

Mayo Clinic opens new C. difficile Clinic at Rochester campus

Clostridium difficile (C. difficile) has reached an epidemic state and is the most common infectious cause of diarrhea in hospitals. Health care providers are seeing increased severity and recurrence rates of the infection. In response, Mayo Clinic has opened a C. difficile Clinic at the Rochester campus.

25 Jun 2013

Rebiotix receives FDA Fast Track designation for RBX2660 to treat patients with CDI

Rebiotix Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track designation for the investigation of RBX2660 (microbiota suspension), intended for the treatment of recurrent Clostridium difficile infection.

25 Jun 2013

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a new study in which linagliptin demonstrated statistically significant reductions in blood glucose levels (HbA1c) after 12 weeks (the study's primary endpoint) in adults with type 2 diabetes (T2D) with moderate to severe renal impairment, compared with placebo. Most patients had T2D for more than ten years (76 percent) and were on insulin (86 percent).

24 Jun 2013

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

Sanofi US (EURONEXT: SAN and NYSE: SNY) announced today data that showed lixisenatide, an investigational once-daily prandial glucagon-like peptide 1 (GLP-1) receptor agonist, decreased HbA1c by reducing PPG (postprandial glucose) daytime exposure when added to standard of care which includes basal insulin with or without oral anti-diabetic agents (OADs). Lixisenatide is for the treatment of adults with type 2 diabetes mellitus.

24 Jun 2013

EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer

Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc. (TSE:4503), and Medivation, Inc. announced that following the regulatory review process by the European Medicines Agency (EMA) and a positive opinion from the Committee for Medicinal Products for Human Use on April 25, 2013, the European Commission (EC) has granted the marketing authorization for XTANDI™ (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.

24 Jun 2013

Rigorous interventions result in fewer infections, deaths associated with hospital-onset C. difficile

Rhode Island Hospital has reduced the incidence of hospital-associated Clostridium difficile (C. difficile) infections by 70 percent and reduced annual associated mortality in patients with hospital-associated C. difficile by 64 percent through successive implementation of five rigorous interventions , as reported in the July 2013 issue of The Joint Commission Journal on Quality and Patient Safety.

21 Jun 2013

Medicago produces Rotavirus VLP vaccine candidate using plant-based manufacturing platform

Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced the successful production of a Rotavirus VLP vaccine candidate comprising all four structural antigens of rotavirus (VP2, VP4, VP6 and VP7) using Medicago's plant-based manufacturing platform.

20 Jun 2013

Diarrhea News and Research

Latest Diarrhea News and Research

Infection control program and active surveillance can reduce incidence of impatient C. diff infections

Soligenix announces personalized medicine collaboration with SciClone

Study identifies genomic regions associated with cholera susceptibility

Scientists uncover easy strategies to prevent harmful side-effects of antibiotics responses

Researchers report that aerobic exercise can lessen or worsen ulcerative colitis symptoms

ARIAD Pharmaceuticals' Iclusig gets EC marketing authorization for CML and Ph+ ALL treatment

Genentech's Perjeta regimen gets FDA Priority Review for HER2-positive early stage breast cancer

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

First clinical study for development of SGX203 to treat pediatric Crohn's disease

EMA's CHMP issues positive opinion for approval of Genzyme's LEMTRADA in Europe

FDA approves Novartis' Exelon Patch for treatment of severe Alzheimer's disease

Physician offers helpful tips to a healthy summer

Eisai submits BELVIQ NDS with Health Canada

Mayo Clinic opens new C. difficile Clinic at Rochester campus

Rebiotix receives FDA Fast Track designation for RBX2660 to treat patients with CDI

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer

Rigorous interventions result in fewer infections, deaths associated with hospital-onset C. difficile

Medicago produces Rotavirus VLP vaccine candidate using plant-based manufacturing platform

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Diarrhea News and Research

Latest Diarrhea News and Research

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Newsletters you may be interested in